Is Idera Pharmaceuticals, Inc. (IDRA) a Sell? The Stock Reaches 52-Week Low Today

July 13, 2018 - By Sheila Anderson

Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Logo

Investors sentiment decreased to 1.57 in 2018 Q1. Its down 2.32, from 3.89 in 2017Q4. It is negative, as 12 investors sold Idera Pharmaceuticals, Inc. shares while 25 reduced holdings. 21 funds opened positions while 37 raised stakes. 91.28 million shares or 35.83% less from 142.24 million shares in 2017Q4 were reported.
218,035 are owned by California State Teachers Retirement Systems. Citigroup Inc has invested 0% in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA). Moreover, Citadel Advisors Ltd Llc has 0% invested in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA). Sg Americas Secs Limited Liability Company holds 15,639 shares. Deutsche Comml Bank Ag holds 150,927 shares. Balyasny Asset Mngmt Lc has 45,916 shares. Tiaa Cref Investment Mgmt accumulated 289,728 shares. Pnc Services Gru Inc reported 2,000 shares stake. Aqr Capital Mngmt Lc invested in 17,631 shares or 0% of the stock. Creative Planning, a Kansas-based fund reported 39,100 shares. Moreover, Guggenheim has 0% invested in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA). Bankshares Of Mellon has 476,933 shares for 0% of their portfolio. First Midwest Savings Bank Trust Division has invested 0.06% in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA). Geode Capital Management Ltd Llc holds 1.47 million shares. The New York-based Millennium Lc has invested 0.01% in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA).

Since January 17, 2018, it had 0 insider purchases, and 1 sale for $480,000 activity.

The stock of Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) hit a new 52-week low and has $0.98 target or 3.00 % below today’s $1.01 share price. The 5 months bearish chart indicates high risk for the $219.48M company. The 1-year low was reported on Jul, 13 by If the $0.98 price target is reached, the company will be worth $6.58M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock.

The stock decreased 4.72% or $0.05 during the last trading session, reaching $1.01. About 3.27M shares traded or 117.33% up from the average. Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) has risen 15.57% since July 13, 2017 and is uptrending. It has outperformed by 3.00% the S&P500.

Analysts await Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) to report earnings on August, 6. They expect $-0.10 earnings per share, up 28.57 % or $0.04 from last year’s $-0.14 per share. After $-0.10 actual earnings per share reported by Idera Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Ratings Coverage

Among 3 analysts covering Idera (NASDAQ:IDRA), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Idera had 3 analyst reports since March 9, 2018 according to SRatingsIntel. The firm earned “Outperform” rating on Wednesday, June 13 by Robert W. Baird. The company was maintained on Wednesday, June 13 by JMP Securities. The rating was maintained by H.C. Wainwright on Friday, March 9 with “Buy”.

More recent Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) news were published by: which released: “American Airlines, Avon Products Plummet into Wednesday’s 52-Week Low Club” on July 11, 2018. Also published the news titled: “Benzinga’s Daily Biotech Pulse: AbbVie Files sNDA For Leukemia Drug, AcelRx Offering, Aurinia Starts Mid-Stage Trial” on July 12, 2018.‘s news article titled: “Idera Pharmaceuticals Announces Termination of Merger Agreement with BioCryst Pharmaceuticals” with publication date: July 10, 2018 was also an interesting one.

Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of oligonucleotide therapeutics for oncology and rare diseases in the United States. The company has market cap of $219.48 million. It uses two drug discovery technology platforms to design and develop drug candidates, including toll-like receptor targeting technology and third-generation antisense technology. It currently has negative earnings. The company's drug candidates include IMO-2125, an agonist that is in Phase I/II clinical trials in combination with ipilimumab and pembrolizumab for the treatment of anti-PD-1 refractory metastatic melanoma and refractory solid tumors; IMO-8400, an antagonist, which is in Phase II clinical trial for the treatment of dermatomyositis.

Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.